Morgan Stanley Raises PT On Covidien To $63

May 12, 2011 5:46 AM | 7 seconds read | Make a Comment

Morgan Stanley has raised the price target on Covidien

COV

from $60 to $63 and maintains its Overweight rating.

Posted In: Price Target Analyst Ratings Covidien Health Care Health Care Equipment Morgan Stanley

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.